Myopericarditis After COVID-19 mRNA Vaccination

Circ J. 2022 Feb 25;86(3):472. doi: 10.1253/circj.CJ-21-0683. Epub 2021 Sep 30.

Authors

Shintaro Sakaguchi¹, Naoki Fujimoto², Kazuhide Ichikawa¹, Daisuke Izumi¹, Koji Katsuta³, Masafumi Takafuji⁴, Kyoko Imanaka-Yoshida⁵, Kaoru Dohi²

Affiliations

¹ Department of Cardiology, Matsusaka Municipal Hospital.
² Department of Cardiology and Nephrology, Mie Universal Graduate School of Medicine.
³ Department of Pathology, Matsusaka Municipal Hospital.
⁴ Department of Radiology, Mie Universal Graduate School of Medicine.
⁵ Department of Pathology and Matrix Biology, Mie Universal Graduate School of Medicine.

PMID: 34588400
DOI: 10.1253/circj.CJ-21-0683

No abstract available

Publication types

Case Reports

MeSH terms

Adverse Drug Reaction Reporting Systems
Aspirin / administration & dosage
Aspirin / therapeutic use
BNT162 Vaccine / administration & dosage
BNT162 Vaccine / adverse effects*
C-Reactive Protein
COVID-19 / complications*
Diuretics / administration & dosage
Diuretics / therapeutic use
Humans
Male
Middle Aged
Myocarditis / chemically induced
Myocarditis / diagnosis*
Myocarditis / drug therapy
Natriuretic Peptide, Brain / blood
RNA, Messenger
SARS-CoV-2
Vaccination / adverse effects

Substances

Diuretics
RNA, Messenger
Natriuretic Peptide, Brain
C-Reactive Protein
BNT162 Vaccine
Aspirin